MRP评分联合IPSI评分对初诊多发性骨髓瘤患者预后的评估价值  

Evaluation value of MRP score combined with IPSI score in prognosis of newly diagnosed multiple myeloma patients

作　　者：叶鉴南 马柯娃 曹永芹 周新[1] 孙超[1] YE Jiannan;MA Kewa;CAO Yongqin;ZHOU Xin;SUN Chao(Department of Haematology,Wuxi People's Hospital Affiliated to Nanjing Medical University,Jiangsu Wuxi 214023,China)

机构地区：[1]南京医科大学附属无锡市人民医院血液科,江苏无锡214023

出　　处：《现代肿瘤医学》2023年第9期1726-1731,共6页Journal of Modern Oncology

摘　　要：目的:探讨真实世界中英国骨髓瘤联盟危险分层评分(UK myeloma research alliance risk profile, MRP)预后评分系统与炎症指数评分(inflammatory prognostic scoring index, IPSI)预后评分系统对基于硼替佐米治疗的初诊多发性骨髓瘤患者的预后评估价值。方法:回顾性分析本院血液科2007年01月01日至2018年06月30日初发的多发性骨髓瘤患者临床及实验室资料,使用两种预后评分系统对患者预后进行评估比较。结果:MRP预后评分系统与IPSI预后评分系统对初诊多发性骨髓瘤患者均可进行危险度分层。且同时符合MRP及IPSI定义的低危或高危组患者的OS和PFS较其他组具有统计学差异。结论:同时具有MRP高危因素及IPSI高危因素的骨髓瘤患者属超高危患者,预后极差,两种简易预后模型的综合应用可以作为现有主流预后模型的补充。Objective:To explore the prognostic value of UK myeloma research alliance risk profile prognostic scoring system and inflammatory prognostic scoring index prognostic scoring system in the real world for newly diagnosed multiple myeloma patients based on bortezomib treatment.Methods:The clinical and laboratory data of patients with initial multiple myeloma in the Department of Hematology of our hospital from January 1,2007 to June 30,2018 were retrospectively analyzed.Two prognostic scoring systems were used to evaluate and compare the prognosis of patients.Results:Both MRP prognostic scoring system and IPSI prognostic scoring system can stratify the risk of newly diagnosed patients with multiple myeloma.The OS and PFS of patients in the low risk or high risk group who met both MRP and IPSI definitions were significantly different from those in other groups.Conclusion:Myeloma patients with both high risk factors for MRP and high risk factors for IPSI belong to ultra-high risk patients with extremely poor prognosis.The comprehensive application of the two simple prognostic models can be used as a supplement to the existing mainstream prognostic models.

关 键 词：多发性骨髓瘤 预后评估 硼替佐米 

分 类 号：R733.3[医药卫生—肿瘤]